SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody).
Armstrong
D J
DJ
Department of Rheumatology, Musgrave Park Hospital, Belfast, UK. oswald17727@hotmail.com
McCarron
M T
MT
Wright
G D
GD
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D008875:Middle Aged; D009188:Myelitis, Transverse / Q000628:therapy*; D011239:Prednisolone / Q000627:therapeutic use; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab; D003520:Cyclophosphamide; D011239:Prednisolone